SCHEMBL3981869

SCHEMBL3981869

CCOC(=O)c1cn(CC)c2ccc(I)c(C)c2c1=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.57
KDM4E B2RXH2 5/20 0.55
ALDH1A1 P00352 5/20 0.55
HTT P42858 3/20 0.55
CYP1A2 P05177 1/20 0.55
TDP1 Q9NUW8 1/20 0.47
HPGD P15428 5/20 0.46
KMT2A Q03164 3/20 0.46
MEN1 O00255 2/20 0.46
MAPT P10636 1/20 0.46
THRB P10828 1/20 0.46
POLB P06746 1/20 0.46
HSD17B10 Q99714 3/20 0.43
RAB9A P51151 2/20 0.42
TSHR P16473 2/20 0.42
STAT3 P40763 1/20 0.42
NR4A2 P43354 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
NPC1 O15118 1/20 0.41
MAPK1 P28482 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14842970 0.81 LMNA (0.58) LMNAKDM4EALDH1A1HTTCYP1A2
SCHEMBL15999545 0.81 LMNA (0.58) LMNAKDM4EALDH1A1HTTCYP1A2
SCHEMBL15999544 0.79 LMNA (0.56) LMNAKDM4EALDH1A1HTTCYP1A2
SCHEMBL15991623 0.78 LMNA (0.55) LMNAKDM4EALDH1A1HTTCYP1A2
SCHEMBL1429954 0.78 LMNA (0.74) LMNAKDM4EALDH1A1HTTCYP1A2
SCHEMBL8112020 0.77 KDM4E (0.54) LMNAKDM4EALDH1A1HTTCYP1A2
SCHEMBL11511295 0.75 LMNA (0.52) LMNAKDM4EALDH1A1HTTCYP1A2
SCHEMBL1431428 0.75 LMNA (0.63) LMNAKDM4EALDH1A1HTTCYP1A2
SCHEMBL11404171 0.75 LMNA (0.54) LMNAKDM4EALDH1A1HTTCYP1A2
SCHEMBL11511297 0.75 LMNA (0.51) LMNAKDM4EALDH1A1HTTCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7569550-B2 14 and 15 membered ring compounds GLAXO GROUP LIMITED (GB) 2009-08-04 US disclosed
US-20070185117-A1 Novel 14 and 15 membrered ring compounds GLAXO GROUP LIMITED (GB) 2007-08-09 US disclosed
EP-1628988-B1 NOVEL 14 AND 15 MEMBERED-RING COMPOUNDS GLAXO GROUP LTD (GB) 2006-10-04 EP disclosed
EP-1628988-A1 NOVEL 14 AND 15 MEMBERED-RING COMPOUNDS GLAXO GROUP LIMITED (GB) 2006-03-01 EP disclosed
WO-2004101586-A1 NOVEL 14 AND 15 MEMBERED-RING COMPOUNDS GLAXO GROUP LIMITED (GB) 2004-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185117-A1 Novel 14 and 15 membrered ring compounds CYP51A1, LSS, IL17A LMNA 2615/4885KDM4E 3840/4885ALDH1A1 2827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.